Aggressive surgery best for first-stage lung cancer
Patients who have a lobectomy to remove early-stage lung cancer live longer than those who have less extensive operation or radiation treatment, according to a study published online in The Annals of Thoracic Surgery.
“Our data suggest that the more aggressively we treat early lung cancer, the better the outcome,” said lead author Alex Bryant, of the School of Medicine at the University of California. “This study is one of the best-powered and detailed analyses to date and suggests that lobectomy is still the preferred treatment of this disease for most patients.”
Using the Veterans Affairs Informatics and Computing Infrastructure (VINCI), Bryant, Dr James Murphy and colleagues identified patients who were diagnosed with early-stage non-small cell lung cancer (NSCLC) between 2006 and 2015, and who were treated with either surgery or radiation. In all, 4069 patients were included: 73% underwent lobectomy, 16% received a sublobar resection and 11% received stereotactic body radiation therapy (SBRT). Lobectomy is the removal of an entire lobe of the lung; sublobar resection is a less extensive operation that includes wedge and segmental resections; and SBRT delivers very high doses of radiation over a short period of time (typically 1–2 weeks), precisely targeting the tumour.
In their analyses, the researchers found that the five-year incidence of cancer death was lowest in the lobectomy group at 23%, with the sublobar group at 32% and SBRT patients at 45%. SBRT also was associated with a 45% increased risk of cancer death compared with lobectomy.
Surgery, though, was not without risks. The study showed that both surgical groups had higher immediate mortality compared to radiation due to operative risks. The 30-day mortality was 1.9% for lobectomy, 1.7% for sublobar resection and 0.5% for SBRT. But as time went on and with longer follow-up, the surgery groups demonstrated superiority to SBRT, with long-term survival favouring surgery, especially lobectomy, over radiation. The five-year overall survival rate for lobectomy patients was 70%, followed by the sublobar resection group at 56% and SBRT at 44%.
“Our data suggest that the higher operative risks of surgery are more than offset by improved survival in the months and years after treatment, particularly for lobectomy,” said Bryant.
Increased use of SBRT
The study also showed that the use of SBRT increased throughout the study period, accounting for 2% of all treatments in 2006 and 19% in 2015. Bryant explained that for patients who are too sick to tolerate a major operation like lobectomy, SBRT makes sense and has become an increasingly common option. Less extensive surgeries, such as sublobar resections, also remain a possibility, but there are ongoing concerns about a higher risk of tumour recurrences, he said. As a result, lobectomy remains the standard treatment for early lung cancer in patients who can tolerate a major surgical procedure.
“The public should be aware that lung cancer — even when caught at a very early stage — is a serious diagnosis and deserves aggressive treatment,” said Bryant.
Lung cancer is the leading cause of cancer death, with more people dying of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for 80–85% of all lung cancer diagnoses, according to the American Cancer Society (ACS). ACS estimates that more than 222,500 Americans will be diagnosed with lung cancer this year, and more than 155,000 lung cancer patients will die. About 14% of all new cancers are lung cancers.
Stroke affects children and babies, and is among the top 10 causes of death in children.
Opting for a nasal spray only strategy may be better than adding hayfever tablets to the mix.
Patients who conversed with avatars in this study experienced significant improvements.